1.Favoriti P, Carbone G, Greco M, Pirozzi F, Pirozzi REM, Corcione F: Worldwide burden of colorectal cancer: a review. Updates in surgery 2016, 68(1):7–11.
2.Lynch HT, De la Chapelle A: Hereditary colorectal cancer. New England Journal of Medicine 2003, 348(10):919–932.
3.Baena R, Salinas P: Diet and colorectal cancer. Maturitas 2015, 80(3):258–264.
4.Rosato V, Guercio V, Bosetti C, Negri E, Serraino D, Giacosa A, Montella M, La Vecchia C, Tavani A: Mediterranean diet and colorectal cancer risk: a pooled analysis of three Italian case–control studies. British journal of cancer 2016, 115(7):862.
5.Chan DS, Lau R, Aune D, Vieira R, Greenwood DC, Kampman E, Norat T: Red and processed meat and colorectal cancer incidence: meta-analysis of prospective studies. PloS one 2011, 6(6):e20456.
6.Shapiro H, Thaiss CA, Levy M, Elinav E: The cross talk between microbiota and the immune system: metabolites take center stage. Current opinion in immunology 2014, 30:54–62.
7.Sekirov I, Russell SL, Antunes LCM, Finlay BB: Gut microbiota in health and disease. Physiological reviews 2010, 90(3):859–904.
8.Sonnenburg ED, Smits SA, Tikhonov M, Higginbottom SK, Wingreen NS, Sonnenburg JL: Diet-induced extinctions in the gut microbiota compound over generations. Nature 2016, 529(7585):212.
9.Louis P, Hold GL, Flint HJ: The gut microbiota, bacterial metabolites and colorectal cancer. Nature reviews microbiology 2014, 12(10):661.
10.Flemer B, Lynch DB, Brown JM, Jeffery IB, Ryan FJ, Claesson MJ, O’riordain M, Shanahan F, O’toole PW: Tumour-associated and non-tumour-associated microbiota in colorectal cancer. Gut 2017, 66(4):633–643.
11.Park CH, Han DS, Oh Y-H, Lee A-r, Lee Y-r, Eun CS: Role of Fusobacteria in the serrated pathway of colorectal carcinogenesis. Scientific reports 2016, 6:25271.
12.Song H, Wang W, Shen B, Jia H, Hou Z, Chen P, Sun Y: Pretreatment with probiotic Bifico ameliorates colitis‐associated cancer in mice: Transcriptome and gut flora profiling. Cancer science 2018, 109(3):666–677.
13.Hu J, Luo H, Wang J, Tang W, Lu J, Wu S, Xiong Z, Yang G, Chen Z, Lan T: Enteric dysbiosis-linked gut barrier disruption triggers early renal injury induced by chronic high salt feeding in mice. Experimental & molecular medicine 2017, 49(8):e370.
14.Thompson KJ, Ingle JN, Tang X, Chia N, Jeraldo PR, Walther-Antonio MR, Kandimalla KK, Johnson S, Yao JZ, Harrington SC: A comprehensive analysis of breast cancer microbiota and host gene expression. PloS one 2017, 12(11):e0188873.
15.Abed J, Emgård JE, Zamir G, Faroja M, Almogy G, Grenov A, Sol A, Naor R, Pikarsky E, Atlan KA: Fap2 mediates Fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumor-expressed Gal-GalNAc. Cell host & microbe 2016, 20(2):215–225.
16.Csardi G, Nepusz T: The igraph software package for complex network research. InterJournal, Complex Systems 2006, 1695(5):1–9.
17.Edgar RC: Search and clustering orders of magnitude faster than BLAST. Bioinformatics 2010, 26(19):2460–2461.
18.McMurdie PJ, Holmes S: phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PloS one 2013, 8(4):e61217.
19.Chang WSW, Chou RH, Wu CW, Chang JY: Human tissue kallikreins as prognostic biomarkers and as potential targets for anticancer therapy. Expert Opinion on Therapeutic Patents 2007, 17(10):1227–1240.
20.Kozich JJ, Westcott SL, Baxter NT, Highlander SK, Schloss PD: Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform. Applenvironmicrobiol 2013, 79(17):5112–5120.
21.Yeom CH, Cho MM, Baek SK, Bae OS: Risk factors for the development of Clostridium difficile-associated colitis after colorectal cancer surgery. Journal of the Korean Society of Coloproctology 2010, 26(5):329.
22.Sfanos KS, Yegnasubramanian S, Nelson WG, De Marzo AM: The inflammatory microenvironment and microbiome in prostate cancer development. Nature Reviews Urology 2018, 15(1):11–24.
23.Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, Ojesina AI, Jung J, Bass AJ, Tabernero J: Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome research 2012, 22(2):292–298.
24.Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW: Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell host & microbe 2013, 14(2):195–206.
25.Castellarin M, Warren RL, Freeman JD, Dreolini L, Krzywinski M, Strauss J, Barnes R, Watson P, Allen-Vercoe E, Moore RA: Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome research 2012, 22(2):299–306.
26.Poovorawan K, Chatsuwan T, Lakananurak N, Chansaenroj J, Komolmit P, Poovorawan Y: Shewanella haliotis associated with severe soft tissue infection, Thailand, 2012. Emerging infectious diseases 2013, 19(6):1019.
27.Tan C-K, Lai C-C, Kuar W-K, Hsueh P-R: Purulent pericarditis with greenish pericardial effusion caused by Shewanella algae. Journal of clinical microbiology 2008, 46(8):2817–2819.
28.Wu M, Wu Y, Deng B, Li J, Cao H, Qu Y, Qian X, Zhong G: Isoliquiritigenin decreases the incidence of colitis-associated colorectal cancer by modulating the intestinal microbiota. Oncotarget 2016, 7(51):85318.
29.Plant N: The human cytochrome P450 sub-family: transcriptional regulation, inter-individual variation and interaction networks. Biochimica et Biophysica Acta (BBA)-General Subjects 2007, 1770(3):478–488.
30.Bethke L, Webb E, Sellick G, Rudd M, Penegar S, Withey L, Qureshi M, Houlston R: Polymorphisms in the cytochrome p 450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1 and colorectal cancer risk. BMC cancer 2007, 7(1):123.
31.Martinez C, Garcia-Martin E, Pizarro R, Garcia-Gamito F, Agúndez J: Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy. British journal of cancer 2002, 87(6):681.
32.Plewka D, Plewka A, Szczepanik T, Morek M, Bogunia E, Wittek P, Kijonka C: Expression of selected cytochrome P450 isoforms and of cooperating enzymes in colorectal tissues in selected pathological conditions. Pathology-Research and Practice 2014, 210(4):242–249.
33.Gervasini G, García-Martín E, Ladero JM, Pizarro R, Sastre J, Martínez C, García M, Diaz-Rubio M, Agúndez JA: Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients. BMC cancer 2007, 7(1):118.
34.Cho LY, Yang JJ, Ko K-P, Ma SH, Shin A, Choi BY, Han DS, Song KS, Kim YS, Chang S-H: Genetic susceptibility factors on genes involved in the steroid hormone biosynthesis pathway and progesterone receptor for gastric cancer risk. PloS one 2012, 7(10):e47603.
35.Doyle LA, Ross DD: Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003, 22(47):7340.
36.Liu HG, Pan YF, You J, Wang OC, Huang KT, Zhang XH: Expression of ABCG2 and its significance in colorectal cancer. Asian Pac J Cancer Prev 2010, 11(4):845–848.
37.Tsunoda S, Okumura T, Ito T, Kondo K, Ortiz C, Tanaka E, Watanabe G, Itami A, Sakai Y, Shimada Y: ABCG2 expression is an independent unfavorable prognostic factor in esophageal squamous cell carcinoma. Oncology 2006, 71(3–4):251–258.
38.Hirano M, Maeda K, Matsushima S, Nozaki Y, Kusuhara H, Sugiyama Y: Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Molecular pharmacology 2005, 68(3):800–807.
39.Enokizono J, Kusuhara H, Sugiyama Y: Involvement of breast cancer resistance protein (BCRP/ABCG2) in the biliary excretion and intestinal efflux of troglitazone sulfate, the major metabolite of troglitazone with a cholestatic effect. Drug metabolism and disposition 2007, 35(2):209–214.
40.Xie G, Wang X, Huang F, Zhao A, Chen W, Yan J, Zhang Y, Lei S, Ge K, Zheng X: Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis. International journal of cancer 2016, 139(8):1764–1775.
41.Ocvirk S, O’Keefe SJ: Influence of bile acids on colorectal cancer risk: potential mechanisms mediated by diet-gut microbiota interactions. Current nutrition reports 2017, 6(4):315–322.